Publication: Recurrence of primary sclerosing cholangitis after liver transplantation
Issued Date
2015-01-01
Resource Type
Other identifier(s)
2-s2.0-84957678856
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Disease Recurrence After Liver Transplantation: Natural History, Treatment and Survival. (2015), 121-134
Suggested Citation
Phunchai Charatcharoenwitthaya, Keith D. Lindor Recurrence of primary sclerosing cholangitis after liver transplantation. Disease Recurrence After Liver Transplantation: Natural History, Treatment and Survival. (2015), 121-134. doi:10.1007/978-1-4939-2947-4_8 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36784
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Recurrence of primary sclerosing cholangitis after liver transplantation
Other Contributor(s)
Abstract
© Springer Science+Business Media New York 2016. Primary sclerosing cholangitis (PSC) is a progressive inflammatory disease of unknown etiology affecting the bile ducts, leading to fibrosis and eventually cirrhosis in most patients. Liver transplantation is the only effective therapy for PSC patients with end-stage liver disease. As a result of increasing number of patients transplanted for PSC, recurrent PSC has become an important condition negatively affecting graft survival and perhaps patient survival. The difficulty of diagnosing recurrent PSC in the allograft is compounded several fold due to a variety of insults seen exclusively after transplantation which may result in biliary stricture. Identification of risk factors for recurrent PSC is important because it may potentially alter the management of patients after transplantation, and might offer clues to the pathogenesis of PSC. As for PSC in the native liver, treatment options are limited for recurrent PSC. For these important entities affecting PSC patients after liver transplantation, we review the current published data on epidemiology, diagnostic criteria, risk factors, graft and patient survival, and treatment of recurrent PSC.